Compare · BBNX vs WST
BBNX vs WST
Side-by-side comparison of Beta Bionics Inc. (BBNX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 28.2x BBNX ($870.1M).
- BBNX has been more active in the news (2 items in the past 4 weeks vs 1 for WST).
- Both have 18 recent analyst ratings on file.
- Company
- Beta Bionics Inc.
- West Pharmaceutical Services Inc.
- Price
- $19.33-2.13%
- $348.50-1.36%
- Market cap
- $870.1M
- $24.52B
- 1M return
- -
- +5.23%
- 1Y return
- -
- +42.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 1
- Recent ratings
- 18
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest BBNX
- William Blair initiated coverage on Beta Bionics
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
- UBS resumed coverage on Beta Bionics with a new price target
- Amendment: Chief Financial Officer Feider Stephen exercised 10,000 shares at a strike of $5.10 and sold $170,387 worth of shares (10,000 units at $17.04) as part of a pre-agreed trading plan (SEC Form 4)
- Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
- Chief Financial Officer Feider Stephen exercised 9,878 shares at a strike of $5.10 and sold $170,387 worth of shares (10,000 units at $17.04) as part of a pre-agreed trading plan, decreasing direct ownership by 0.07% to 165,931 units (SEC Form 4)
- Chief Commercial Officer Hopman Mark sold $18,880 worth of shares (1,258 units at $15.01) as part of a pre-agreed trading plan, decreasing direct ownership by 0.96% to 129,354 units (SEC Form 4)
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target